Article
Pharmacology & Pharmacy
Xin Li, Jie Huang, Yao Qiu, Qianyun Zhang, Shaoyu Yang, Kan Wu, Jiaoli Wang, Limin Wang, Jian Ye, Shenglin Ma, Bing Xia, Xueqin Chen
Summary: This study demonstrated that pemetrexed-platinum plus bevacizumab was more effective than chemotherapy alone in Chinese patients with advanced non-small-cell lung cancer. The combination therapy significantly improved objective response rate and progression-free survival, but did not impact overall survival. Treatment, gender, adrenal metastasis, and liver metastasis were identified as independent risk factors for progression-free survival.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Yen-Yu Lin, Yu-Chao Wang, Da-Wei Yeh, Chen-Yu Hung, Yi-Chen Yeh, Hsiang-Ling Ho, Hsiang-Chen Mon, Mei-Yu Chen, Yu-Chung Wu, Teh-Ying Chou
Summary: Lung adenocarcinoma has a tendency to metastasize to the brain, leading to significant morbidity and mortality. By analyzing primary tumors, it is possible to identify patients at the highest risk for brain metastasis, which can aid medical decision-making. Further research is needed to understand the mechanisms behind these associations and identify potential treatment targets.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Surgery
Emily Papai, Avinoam Nevler, Charalambos Solomides, Mandeep S. Shergill, Theresa P. Yeo, Shawnna Cannaday, Charles J. Yeo, Jordan M. Winter, Harish Lavu
Summary: Cytologic sampling from ex vivo specimen irrigation after surgical resection of pancreatic and periampullary adenocarcinoma may have implications for locoregional recurrence, survival, and treatment.
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS
(2022)
Article
Oncology
Bharathi Muthusamy, Kira Raskina, Katherine T. Lofgren, Gerald Li, Khaled Tolba, Karen Schwed, Emily Castellanos, Richard S. P. Huang, Geoffrey R. Oxnard, Alexa B. Schrock, Nathan Pennell
Summary: This study assessed the potential value of multi-gene testing in early lung adenocarcinoma (LUAD), and found that it can help accelerate treatment and reduce costs. Early LUAD patients with driver alterations such as ALK, ROS1 or RET mutations can avoid the use of immune checkpoint inhibitors (ICI) to save treatment costs.
JOURNAL OF THORACIC ONCOLOGY
(2023)
Article
Genetics & Heredity
Ying Cai, Chunlan Zhu, Yanfei Wang, Yiqian Jiang, Zhongxin Zhu
Summary: This study identified differentially expressed circRNAs in LUAD-BM using high-throughput sequencing and qRT-PCR, and predicted their potential functions and pathways. The results suggest that these differentially expressed circRNAs play important roles in the occurrence and development of LUAD-BM, and circ_0096442 may be a biomarker for LUAD-BM.
FRONTIERS IN GENETICS
(2022)
Article
Radiology, Nuclear Medicine & Medical Imaging
Ho Yun Lee, Young Lyun Oh, Sung Yoon Park
Summary: Biphasic CT is a reliable method for characterizing hyperattenuating adrenal lesions in patients with lung cancer, providing valuable diagnostic information and high accuracy. Inter-reader agreement was also high, indicating consistency in the assessment of adrenal lesions.
EUROPEAN RADIOLOGY
(2021)
Article
Multidisciplinary Sciences
Alice Yu, Yuanyuan Li, Irene Li, Michael G. Ozawa, Christine Yeh, Aaron E. Chiou, Winston L. Trope, Jonathan Taylor, Joseph Shrager, Sylvia K. Plevritis
Summary: The study introduces a graph-based algorithm REMI that predicts ligand-receptor (LR) interactions and reconstructs interactomes from RNA sequencing data. By leveraging single-cell transcriptomics data for cell type resolution and identifying LR prognostic signatures among tumor-stroma-immune subpopulations, the study confirmed an interaction associated with LUAD progression.
Article
Oncology
Milan Zhang, Jiayi Tong, Weifeng Ma, Chongliang Luo, Huiqin Liu, Yushu Jiang, Lingzhi Qin, Xiaojuan Wang, Lipin Yuan, Jiewen Zhang, Fuhua Peng, Yong Chen, Wei Li, Ying Jiang
Summary: This study investigates prognostic indicators for lung adenocarcinoma with leptomeningeal metastases (LM) and develops an updated graded prognostic assessment model integrated with molecular alterations (molGPA). By analyzing data from 162 patients, the study identifies four predictors and successfully develops a new prognostic model with improved predictive performance.
FRONTIERS IN ONCOLOGY
(2022)
Article
Medicine, General & Internal
Hadeel K. Al Fares, Sierra Abdullaj, Neriman Gokden, Lakshmi P. Menon
Summary: This article presents a rare case of lung adenocarcinoma metastasizing to the adrenal gland, which presented as an adrenal incidentaloma in an asymptomatic patient with no known history of malignancy. The patient was not eligible for surgical treatment due to comorbidities, and a biopsy confirmed metastatic lung adenocarcinoma. The patient was subsequently started on chemotherapy.
CUREUS JOURNAL OF MEDICAL SCIENCE
(2022)
Article
Nanoscience & Nanotechnology
Z. Fereshteh, M. N. Dang, C. Wenck, E. S. Day, J. H. Slater
Summary: This study investigated the efficacy of inhibiting cancer cell binding to human lung microvascular endothelial cells (HMVEC-Ls) via antibody blocking of E-selectin using antibody-functionalized gold nanoshells (NS). The results demonstrated that E-selectin-targeted NS reduced the binding of MDA-MB-231 cancer cells to HMVEC-Ls by up to 41%, suggesting the potential of these conjugates in inhibiting cancer cell extravasation during metastasis.
ACS APPLIED NANO MATERIALS
(2023)
Article
Pharmacology & Pharmacy
Haitao Liu, Yahua Li, Zongming Li, Xinwei Han, Kewei Ren
Summary: The study evaluated the efficacy and safety of bevacizumab-loaded CalliSpheres (R) bronchial arterial chemoembolization combined with immunotherapy and targeted therapy in patients with lung adenocarcinoma. The results showed that this treatment method has good tolerability and efficacy.
FRONTIERS IN PHARMACOLOGY
(2023)
Article
Biochemistry & Molecular Biology
Zhen Liu, Jiahao Liu, Yang Li, Hao Wang, Zixi Liang, Xiaojie Deng, Qiaofen Fu, Weiyi Fang, Ping Xu
Summary: The downregulation of VPS33B in tumors is a factor that promotes the progression of lung adenocarcinoma (LUAD). Mechanistic studies show that VPS33B inhibits EGFR Ras/ERK signaling, leading to reduced expression of oncogenic factors like c-Myc. Additionally, the interaction between VPS33B and NESG1 affects LUAD migration and invasion through different signaling pathways.
Review
Oncology
Yuying Liu, Xinyue Dong, Tao Li, Yanke Xing, Na Liu
Summary: This article reports a case of lung adenocarcinoma metastatic to the bladder and includes a literature review to provide clinicians with diagnostic and treatment experience and help avoid misdiagnosis and mistreatment.
FRONTIERS IN ONCOLOGY
(2023)
Article
Oncology
Jie Liu, Wang-yang Xu, Maosong Ye, Zilong Liu, Chun Li
Summary: LUAD patients in eastern China exhibit a unique profile of mutations with the most commonly mutated genes being EGFR and TP53. Targeted DNA panel analysis is essential for personalized treatment decisions, as specific mutations can impact the efficacy of targeted therapies. Additionally, CEBPA mutations were found to affect the response to EGFR-tyrosine kinase inhibitors, and tumors with ERBB2, CEBPA, and TCF7L2 mutations tend to have higher tumor mutation burden (TMB).
FRONTIERS IN ONCOLOGY
(2021)
Article
Pharmacology & Pharmacy
Weiyu Wang, Shengyao Ma, Zhenyu Ding, Yang Yang, Huaijie Wang, Kunning Yang, Xiaoshan Cai, Hanyue Li, Zhiqin Gao, Meihua Qu
Summary: XPC expression levels in lung adenocarcinoma have been found to influence patients' prognosis and inhibit tumor invasion and metastasis by regulating the stemness of lung cancer cells.
FRONTIERS IN PHARMACOLOGY
(2021)